BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Clinical Trials
2.6k
Trial Phases
5 Phases
Drug Approvals
283
Drug Approvals
Aflibercept Intravitreous Injection
- Product Name
- 艾力雅
- Approval Number
- 国药准字SJ20255004
- Approval Date
- May 19, 2025
Recombinant human interferon beta-1b for injection
- Product Name
- 倍泰龙
- Approval Number
- 国药准字SJ20130094
- Approval Date
- Aug 24, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140940
- Approval Date
- Apr 25, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140941
- Approval Date
- Apr 25, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140939
- Approval Date
- Apr 25, 2023
Aflibercept Intravitreous Injection
- Product Name
- 艾力雅
- Approval Number
- 国药准字SJ20180010
- Approval Date
- Apr 10, 2023
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
Distribution across different clinical trial phases (2062 trials with phase data)• Click on a phase to view related trials
A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants
- Conditions
- Vasomotor Symptoms
- Interventions
- Drug: Treatment ADrug: Treatment BDrug: Treatment C
- First Posted Date
- 2025-11-17
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT07229404
- Locations
- 🇨🇦
Altasciences, Mount Royal, Quebec, Canada
An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia
- Conditions
- Metastatic Hormonesensitive Prostate Cancer (mHSPC)
- First Posted Date
- 2025-10-31
- Last Posted Date
- 2025-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1000
- Registration Number
- NCT07223372
BAY3401016; Biomarker Study Alport
- Conditions
- Alport Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-11-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT07211685
- Locations
- 🇺🇸
Nephrology Clinic at The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States
🇺🇸The Peggy and Harold Katz Family Drug Discovery Center - Nephrology, Miami, Florida, United States
🇺🇸Center for Advanced Pediatrics - Nephrology, Atlanta, Georgia, United States
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
- Conditions
- Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)
- Interventions
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 117
- Registration Number
- NCT07192952
- Locations
- 🇺🇸
Children's Hospital Colorado - Anschutz Medical Campus - Cardiology, Aurora, Colorado, United States
🇺🇸Nemours Children's Hospital -Delaware, Wilmington, Delaware, United States
🇺🇸UF Health Shands Hospital - Pediatric Cardiology, Gainesville, Florida, United States
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
- Conditions
- Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-11-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 111
- Registration Number
- NCT07188805
- Locations
- 🇺🇸
Children's Hospital Colorado - Anschutz Medical Campus - Cardiology, Aurora, Colorado, United States
🇺🇸Nemours Children's Hospital -Delaware, Wilmington, Delaware, United States
🇺🇸UF Health Shands Hospital - Pediatric Cardiology, Gainesville, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 329
- Next
News
Galmed Reports Promising Triple-Drug Combination for Gastrointestinal Cancers
Galmed Pharmaceuticals announced top-line results showing synergistic effects of Aramchol, Stivarga (regorafenib), and metformin in killing gastrointestinal tumor cells both in vivo and in vitro.
WRN Inhibitors Enter Clinical Development Phase as Precision Oncology Market Expands
WRN inhibitors represent a fast-emerging precision oncology segment targeting DNA repair vulnerabilities in microsatellite instability-high (MSI-H) tumors through synthetic lethality mechanisms.
UK High Court Clears Path for Alvotech's Eylea Biosimilar Manufacturing Ahead of Patent Expiry
The UK High Court rejected Regeneron and Bayer's injunction request against Alvotech's manufacturing of AVT06, a biosimilar to Eylea (aflibercept), allowing continued production at the company's UK contract manufacturing organization.
Finerenone Shows Promise as First New Type 1 Diabetes Kidney Treatment in 30 Years
A Phase 3 clinical trial demonstrated that finerenone (Kerendia) reduced protein loss in urine by approximately 25% in 242 type 1 diabetes patients with chronic kidney disease over six months.
Hemlibra Demonstrates Exercise-Related Bleeding Prevention in Hemophilia A as Pfizer Reports Positive Phase III BAISIS Results
Hemlibra has shown efficacy in preventing bleeding during exercise for patients with Hemophilia A, marking a significant advancement in activity-related bleeding management.
ORIC Pharmaceuticals Completes Dose Exploration for ORIC-944 in Prostate Cancer, Shows Promising Efficacy Signals
ORIC Pharmaceuticals completed the dose exploration portion of its Phase 1b trial for ORIC-944, a PRC2 inhibitor, in combination with AR inhibitors for metastatic castration-resistant prostate cancer.
AstraZeneca Establishes Sixth Global R&D Center in Beijing to Accelerate AI-Driven Drug Discovery
AstraZeneca officially opened its sixth global strategic R&D center in Beijing's BioPark, marking the company's second facility in China alongside its Shanghai center.
Medherant's Testosterone Patch Shows Promise in Phase 1 Trial for Menopausal Women
Medherant's TEPI Patch successfully restored testosterone blood levels to normal pre-menopausal ranges in post-menopausal women during Phase 1 clinical testing at Hammersmith Medicines Research in London.
New Report Analyzes 1,775 Clinical-Stage Pharma Partnerships from 2020-2025
ResearchAndMarkets.com released a comprehensive report analyzing 1,775 clinical-stage partnering deals in pharma and biotech from 2020-2025, providing detailed financial terms and strategic insights.
AskBio Reports Positive Interim Safety Data for AB-1003 Gene Therapy in Rare Muscular Dystrophy Trial
AskBio presented interim safety results from the Phase 1/2 LION-CS101 trial showing no dose-limiting toxicities or serious adverse events for AB-1003 gene therapy in LGMD2I/R9 patients up to 52 weeks post-treatment.